Pharmaron Beijing Co Ltd
HKEX:3759
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
P
|
Pharmaron Beijing Co Ltd
HKEX:3759
|
CN |
|
S
|
Sparx Technology Inc
XTSX:SPRX
|
CA |
|
N
|
Noble Group Holdings Ltd
SGX:CGP
|
HK |
|
Ningbo Shimao Energy Co Ltd
SSE:605028
|
CN |
|
P
|
Petroleum General Distribution Services JSC
VN:PSD
|
VN |
|
V
|
Volkswagen AG
SWB:VOW3
|
DE |
|
Kuber Resources Corp
OTC:KUBR
|
HK |
|
B
|
Beauty Farm Medical & Health Industry Inc
HKEX:2373
|
CN |
|
R
|
RHT Health Trust
SGX:RF1U
|
SG |
|
D
|
Dimeco Inc
OTC:DIMC
|
US |
|
E
|
Empower India Ltd
BSE:504351
|
IN |
|
Rattanindia Enterprises Ltd
NSE:RTNINDIA
|
IN |
Wall Street
Price Targets
Price Targets Summary
Pharmaron Beijing Co Ltd
According to Wall Street analysts, the average 1-year price target for
Pharmaron Beijing Co Ltd
is 26.25 HKD
with a low forecast of 17.73 HKD and a high forecast of 32.3 HKD.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is Pharmaron Beijing Co Ltd's stock price target?
Price Target
26.25
HKD
According to Wall Street analysts, the average 1-year price target for
Pharmaron Beijing Co Ltd
is 26.25 HKD
with a low forecast of 17.73 HKD and a high forecast of 32.3 HKD.
What is Pharmaron Beijing Co Ltd's Revenue forecast?
Projected CAGR
15%
For the last 8 years the
compound annual growth rate for
Pharmaron Beijing Co Ltd's revenue is
29%.
The projected
CAGR
for the next 3 years is
15%.
What is Pharmaron Beijing Co Ltd's Operating Income forecast?
Projected CAGR
21%
For the last 8 years the
compound annual growth rate for
Pharmaron Beijing Co Ltd's operating income is
33%.
The projected
CAGR
for the next 3 years is
21%.
What is Pharmaron Beijing Co Ltd's Net Income forecast?
Projected CAGR
13%
For the last 8 years the
compound annual growth rate for
Pharmaron Beijing Co Ltd's net income is
34%.
The projected
CAGR
for the next 3 years is
13%.
